Injectable @entity8466 as a nonsurgical treatment for XXXX .

@entity1 @entity8466 @entity397 @entity56 @entity2074
OBJECTIVE: Nonsurgical treatment of @entity2074 using @entity8466 ( @entity8466 ). INDICATIONS: Metacarpophalangeal (MP) joint (20-100  ) and proximal interphalangeal (PIP) joint (20-80  ) contractures. CONTRAINDICATIONS: Pregnancy, previous @entity56 to collagenase or excipients, anticoagulant use within 7  days prior to treatment. INJECTION TECHNIQUE: @entity8466 injected directly into the Dupuytren's cord weakening the contracted cord. After injection, the @entity1 returns the following day to allow @entity8466 to lyse the collagen within the cord. An extension force is then applied to the involved finger to disrupt the weakened cord. POSTMANIPULATION MANAGEMENT: Use of extension splint at night, movement instructions during the day. RESULTS: A total of 120  @entity1 (107 @entity1 ; 13 @entity1 ; mean age 62  years, range 30-84  years) were treated. In 49   % the little finger, in 44   % the ring finger, in 4   % the middle finger, and in 3   % the index finger was treated. Full release was achieved in 71   %, partial release in 26   %, and no change in 3   % of @entity1 . The median pretreatment contracture for the MP joint was 37   (range 25-100  ) and PIP joint 51   (range 30-97  ). At 12  months, the mean contracture for the MP joint was 9   (range 0-25  ) and for the PIP joint 21   (range 10-36  ). Adverse events observed in 96   % of @entity1 for 3  months . No @entity397 , anaphylactic reactions, or nerve or ligament injuries observed.
